Amgen CEO Optimistic About Weight Loss Drug's Long-Term Efficacy

Amgen CEO Bob Bradway believes the company's experimental GLP-1 drug, MariTide, can help patients maintain weight loss long-term by addressing the "patient persistence issue." The drug showed patients could maintain weight loss for two years with a monthly injection, and Amgen is studying different doses and frequencies of administration. Bradway also discussed the company's acquisition of Horizon Therapeutics, saying it plays to Amgen's strengths in biologics and autoimmunity.